Seapolynol

Botamedi is a South Korean biotechnology company specializing in the development of marine-derived bioactive compounds, most notably Seapolynol. Seapolynol is a proprietary extract of phlorotannins derived from the brown alga Ecklonia cava, which has received New Dietary Ingredient (NDI) status from the FDA and Novel Food status from the EFSA. The company focuses on the therapeutic potential of these marine polyphenols in treating chronic inflammatory conditions, metabolic syndrome, and neurodegenerative diseases. Botamedi operates a vertically integrated model from raw material harvesting to clinical research and commercialization of functional foods and pharmaceutical candidates.